Alpha 2.0
Login Register
» Articles » PMID: 39826478

Real-world Outcomes of PARP Inhibitor Maintenance in Advanced Ovarian Cancer: a Focus on Disease Patterns and Treatment Modalities at Recurrence

Overview
Journal ESMO Open
Publisher Elsevier
Date 2025 Jan 18
PMID 39826478
Authors
M Loverro
C Marchetti
V Salutari
D Giannarelli
L Vertechy
F M Capomacchia
C Caricato
M Campitelli
C Panico
G Avesani
F Cocciolillo
A Rosati
G Scambia
A Fagotti
Affiliations
Soon will be listed here.
Abstract

Background: The utilization of poly-ADP-ribose polymerase (PARP) inhibitors (PARPi) as a first-line maintenance therapy for advanced ovarian cancer has increased significantly, with ∼80% of patients potentially eligible. This expansion has led to a rise in the population experiencing platinum-sensitive recurrence, yet data on first recurrence during PARPi are limited. This real-world study from a high-volume referral center aims to elucidate recurrence rates, disease distribution, and treatment modalities at the time of progression in PARPi-treated patients.

Materials And Methods: We analyzed our prospectively maintained database to identify patients receiving first-line PARPi maintenance from January 2019 to December 2022 at our institution.

Results: A total of 373 cases were identified, 51.5% of which had a BRCA mutation. With a median follow-up of 38 months, 44.8% of patients experienced recurrence, with 90.3% having a platinum-free interval exceeding 6 months. Recurrences were oligometastatic in 44.9% of cases, with BRCA mutations strongly predicting this pattern (hazard ratio 3.014, confidence interval 1.486-6.113, P = 0.002). The median progression-free survival was 39 months, significantly longer for BRCA-mutated and homologous recombination deficiency-positive patients. Over one-third of platinum-sensitive recurrent patients were candidates for local treatments, and PARPi administration was prolonged in 53.7%.

Conclusions: Despite the notable survival improvement, a significant proportion of the population will experience a platinum-sensitive recurrence on PARPi, for which local treatments are often a viable option. Our study highlights the need for further research to determine whether the ablation of oligometastatic sites has a significant impact on post-recurrence survival and to identify if there are patient categories that would benefit from personalized follow-up due to their susceptibility to oligometastatic recurrences and local treatments.

References
1.
Kamrava M, Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Mirza M . Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012. Gynecol Oncol. 2024; 189:68-74. DOI: 10.1016/j.ygyno.2024.07.006. View
2.
Palluzzi E, Marchetti C, Cappuccio S, Avesani G, Macchia G, Gambacorta M . Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance. Int J Gynecol Cancer. 2022; 32(9):1164-1170. DOI: 10.1136/ijgc-2022-003543. View
3.
Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, DAgostino G . A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. Oncologist. 2020; 25(2):e311-e320. PMC: 7011643. DOI: 10.1634/theoncologist.2019-0309. View
4.
Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick C . Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023; 189:112908. DOI: 10.1016/j.ejca.2023.04.024. View
5.
Nedelcu R, Liede A, Aube J, Finch A, Kwan E, Jack E . BRCA mutations in Italian breast/ovarian cancer families. Eur J Hum Genet. 2002; 10(2):150-2. DOI: 10.1038/sj.ejhg.5200755. View